Nano-X Imaging Remains Underwhelming Despite Recent Wins

Nano-X Imaging remains a 'sell' due to weak revenue growth, worsening losses, and limited traction in its core business. NNOX's advanced imaging technology and AI offerings have yet to translate into significant sales, with most revenue still from teleradiology services. Recent partnerships and acquisitions, including VasoHealthcare IT and European distribution deals, offer potential but lack a clear financial impact.

Seeking Alpha • Nov 27, 2025

Why Nano X Imaging Stock Crushed it Today

It signed a distribution deal with a French partner. This followed similar arrangements made in other European countries.

The Motley Fool • Nov 25, 2025

Nanox Engages with Althea France to Accelerate European Commercialization of Nanox.ARC System

Althea France, part of  one of Europe's largest independent medical technology services provider s , to distribute CE-marked Nanox.ARC system across French healthcare sector

GlobeNewsWire • Nov 25, 2025

Nanox.AI Bone Solutions, Advanced AI-Powered Software for Spine Assessment, Recommended by NICE for Early Value Assessment in UK National Health Service hospitals

Nanox's HealthOST and HeathVCF recommended for use in UK National Health Service hospitals for a three-year period as the use of AI solutions in bone disease is evaluated

GlobeNewsWire • Nov 24, 2025

Nanox Announces $15 Million Registered Direct Offering of Common Stock

PETACH TIKVA, Israel, Nov. 23, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company”, Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 3,826,530 ordinary shares (“Common Stock”) in a registered direct offering. The offering is expected to result in gross proceeds of approximately $15 million, before deducting offering expenses.

GlobeNewsWire • Nov 24, 2025

Why Nano-X Imaging Stock Skyrocketed by 26% on Friday

The visualization specialist posted its third quarter results. It beat on the bottom line and missed slightly on revenue, but investors were cheered by other developments.

The Motley Fool • Nov 21, 2025

Nano-X Imaging Ltd. (NNOX) Q3 2025 Earnings Call Transcript

Nano-X Imaging Ltd. ( NNOX ) Q3 2025 Earnings Call November 20, 2025 8:30 AM EST Company Participants Mike Cavanaugh - IR-ICR Westwicke Erez Meltzer - CEO & Acting Chairman of the Board Ran Daniel - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald & Co., Research Division Jeffrey Cohen - Ladenburg Thalmann & Co. Inc., Research Division Scott Henry - Alliance Global Partners, Research Division Presentation Operator Good day, and thank you for standing by.

Seeking Alpha • Nov 20, 2025

Nanox Reaches Agreement with Vaso Corporation to Acquire VasoHealthcare IT, Accelerating U.S. Rollout of AI Solutions

PETACH TIKVA, Israel, Nov. 19, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company”, Nasdaq: NNOX), an innovative medical imaging technology company, today announced that the parties have agreed on the terms and conditions pursuant to which Nanox will acquire VasoHealthcare IT Inc . (“VHC IT”) from Vaso Corporation (“Vaso”) (OTCQX: VASO), subject to certain conditions.

GlobeNewsWire • Nov 19, 2025

Vaso Corporation Announces Divestiture of Subsidiary

Vaso Corporation 137 Commercial StreetPlainview, New York 11803Tel: (516) 997-4600 Fax: (516) 997-2299 Investor Contact: Jonathan NewtonInvestor RelationsPhone: 516-997-4600 Email: [email protected] PLAINVIEW, N.Y, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Vaso Corporation (“Vaso”) (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and healthcare IT services, professional sales services and proprietary medical products, announced today that it had reached an agreement, subject to certain conditions, with Nano-X Imaging Ltd. (“Nanox”) (Nasdaq: NNOX), an innovative medical imaging technology company, to sell one of its subsidiaries, VasoHealthcare IT Corp. The parties intend to complete the sale within a couple of weeks.

GlobeNewsWire • Nov 19, 2025

Nanox to Launch FDA-Cleared Nanox.ARC X and Present development of new AI innovations at RSNA 2025 Annual Meeting

Live demonstrations of Nanox.ARC X to be featured at RSNA booth ( 3914, South Hall Level 3) every 30 minutes Innovation Theater p resentation to highlight development of pulmonary nodule AI solution, as future component of Nanox.ARC X ; Dec 2 at 11:00am (Innovation Theater, Booth # 3316, South Hall A ) Poster p resentation : “Applications of Digital Tomosynthesis in the Musculoskeletal System” (Learning Center, East Level 3) Dr. Lawrence Tanenbaum to host cocktail event featur ing discussion about the future of radiology and AI ; Dec 1 at 5:30pm (VU Rooftop Bar , Hilton Garden ) PETACH TIKVA, Israel, Nov. 13, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company”, Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will showcase its Nanox.ARC X multi-source digital tomosynthesis system and highlight development of new solutions for its AI portfolio at the Radiological Society of North America (RSNA) 2025 Annual Meeting, being held November 30 - December 4, 2025 in Chicago, IL. The Nanox.ARC X, an AI-ready, multi-source digital tomosynthesis system that makes advanced 3D imaging possible in more places at significantly lower cost and radiation dose than CT, received FDA 510(k) clearance in April 2025 for general use, including musculoskeletal, pulmonary, intra-abdominal and paranasal indications.

GlobeNewsWire • Nov 13, 2025